Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection

Medical Microbiology and Immunology

Volumn 203, Issue 2, 2014, Pages 115-123

  Frenzel, K ^a   Lehmann, J ^a   Kruger D H ^a   Martin Parras, L ^b   Uharek, L ^a   Hofmann, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b 4 Antibody AG   (Switzerland)

Author keywords

ADCC; CMV; EBV; Neutralization; NK cells

Indexed keywords

CD20 ANTIBODY; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SM5-1; RITUXIMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG FIBROBLAST; LYMPHOBLASTOID CELL LINE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PURIFICATION; SERODIAGNOSIS; CELL CULTURE; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS; KILLER CELLS, NATURAL;

EID: 84898058072     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-013-0321-2     Document Type: Article

References (31)

1. Boeckh M, Ljungman P (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719
2. Boeckh M, Leisenring W, Riddell SR et al (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407-414
3. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M (2002) High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185:273-282
4. Aalto SM, Linnavuori K, Peltola H et al (1998) Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 56:186-191
5. Chen DB, Song QJ, Chen YX, Chen YH, Shen DH (2013) Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97:117-124
6. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A (2008) CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transpl 22:89-97
7. Kotton CN, Kumar D, Caliendo AM et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795
8. Ljungman P, Reusser P, de la Camara R et al (2004) Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transpl 33:1075-1081
9. Travi G, Pergam SA (2013) Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med [Epub ahead of print]
10. Ljungman P (2008) CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transpl 42(Suppl 1):S70-S72
11. Patriarca F, Medeot M, Isola M et al (2013) Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis 15:259-267
12. Faraci M, Caviglia I, Morreale G et al (2010) Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transpl 45:1052-1055
13. Styczynski J, Gil L, Tridello G et al (2013) Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working group of the European group for blood and marrow transplantation. Clin Infect Dis 57(6):794-802
14. Frenzel K, Ganepola S, Michel D et al (2012) Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. Med Microbiol Immunol 201:277-286
15. Klein M, Schoppel K, Amvrossiadis N, Mach M (1999) Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol 73:878-886
16. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G (2011) Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 52:113-118
17. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-CMV neutralizing antibody response in CMV-HIG. J Virol 86:7444-7447
18. Potzsch S, Spindler N, Wiegers AK et al (2011) B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7:e1002172
19. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359-7368
20. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
21. Manches O, Lui G, Chaperot L et al (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949-954
22. Deckers M, Hofmann J, Kreuzer KA et al (2009) High genotypic diversity and a novel variant of human cytomegalovirus revealed by combined UL33/UL55 genotyping with broad-range PCR. Virol J 6:210
23. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993) Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67:703-710
24. Boeckh M, Bowden RA, Storer B et al (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 7:343-351
25. Otto C, Oltmann A, Stein A et al (2011) Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis. Neurology 76:1316-1321
26. Li L, Coelingh KL, Britt WJ (1995) Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol 69:6047-6053
27. Zaia JA, Sun JY, Gallez-Hawkins GM et al (2009) The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transpl 15:315-325
28. Kuijpers TW, Baars PA, Dantin C, van den BM, van Lier RA, Roosnek E (2008) Human NK cells can control CMV infection in the absence of T cells. Blood 112:914-915
29. Lang P, Griesinger A, Hamprecht K et al (2004) Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors. Hum Immunol 65:423-431
30. Homman-Loudiyi M, Hultenby K, Britt W, Soderberg-Naucler C (2003) Envelopment of human cytomegalovirus occurs by budding into Golgi-derived vacuole compartments positive for gB, Rab 3, trans-golgi network 46, and mannosidase II. J Virol 77:3191-3203
31. Powers C, DeFilippis V, Malouli D, Fruh K (2008) Cytomegalovirus immune evasion. Curr Top Microbiol Immunol 325:333-359